Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone

被引：1
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Bradstock, Kenneth Francis [2 ]
Bendall, Linda J. [3 ]
机构：
[1] Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
[2] Westmead Hosp, Westmead, NSW 2145, Australia
[3] Westmead Millennium Inst, Westmead, NSW, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3575.3575
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1526 / 1526
页数：1
相关论文
共 50 条
  • [41] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Maria Serova
    Armand de Gramont
    Annemilaï Tijeras-Raballand
    Célia Dos Santos
    Maria Eugenia Riveiro
    Khemaies Slimane
    Sandrine Faivre
    Eric Raymond
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1297 - 1307
  • [42] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [43] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [44] Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models
    Rossetti, Stefano
    Broege, Aaron
    Sen, Adrish
    Khan, Salmaan
    MacNeil, Ian
    Molden, Jhomary
    Gorbatchevsky, Igor
    Sullivan, Brian F.
    Laing, Lance
    CANCER RESEARCH, 2024, 84 (09)
  • [45] 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
    Liu, Kevin K-C.
    Bagrodia, Shubha
    Bailey, Simon
    Cheng, Hengmiao
    Chen, Hui
    Gao, Lisa
    Greasley, Samantha
    Hoffman, Jacqui E.
    Hu, Qiyue
    Johnson, Ted O.
    Knighton, Dan
    Liu, Zhengyu
    Marx, Matthew A.
    Nambu, Mitchell D.
    Ninkovic, Sacha
    Pascual, Bernadette
    Rafidi, Kristina
    Rodgers, Caroline M-L.
    Smith, Graham L.
    Sun, Shaoxian
    Wang, Haitao
    Yang, Anle
    Yuan, Jing
    Zou, Aihua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (20) : 6096 - 6099
  • [46] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [47] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [48] Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
    Yuan, Jing
    Garza, Scott J.
    Cao, Joan
    Fisher, Timothy S.
    Lee, Nathan V.
    Eisele, Koleen
    Pasis, Angela
    Hook, Kenneth
    Christensen, James G.
    Kan, Julie L.
    CANCER RESEARCH, 2012, 72
  • [49] Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC
    Moore, Gillian
    Heavey, Susan
    O'Byrne, Kenneth
    Finn, Stephen
    Cuffe, Sinead
    O'Neill, Michael
    Gately, Kathy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1277 - S1278
  • [50] Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response?
    Ekshyyan, Oleksandr
    Anandharaj, Arunkumar
    Nathan, Cherie-Ann O.
    CLINICAL CANCER RESEARCH, 2013, 19 (14) : 3719 - 3721
12345